Omnicell (OMCL) Competitors

Masimo (NASDAQ:MASI) and Omnicell (NASDAQ:OMCL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, risk, media sentiment, profitability and valuation.

Is MASI or OMCL more profitable?

Omnicell has a net margin of 2.01% compared to Masimo's net margin of -24.85%. Masimo's return on equity of 26.54% beat Omnicell's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Masimo	-24.85%	26.54%	11.49%
Omnicell	2.01%	4.27%	2.44%

Do analysts prefer MASI or OMCL?

Masimo currently has a consensus price target of $193.60, indicating a potential upside of 32.13%. Omnicell has a consensus price target of $46.71, indicating a potential upside of 40.88%. Given Omnicell's higher probable upside, analysts clearly believe Omnicell is more favorable than Masimo.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Masimo	0 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.83
Omnicell	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.57

Does the media prefer MASI or OMCL?

In the previous week, Masimo had 15 more articles in the media than Omnicell. MarketBeat recorded 21 mentions for Masimo and 6 mentions for Omnicell. Omnicell's average media sentiment score of 1.71 beat Masimo's score of 0.69 indicating that Omnicell is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Masimo	9 Very Positive mention(s)	3 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Positive
Omnicell	6 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Which has more volatility & risk, MASI or OMCL?

Masimo has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Omnicell has a beta of 0.78, meaning that its stock price is 22% less volatile than the S&P 500.

Which has stronger valuation & earnings, MASI or OMCL?

Omnicell has lower revenue, but higher earnings than Masimo. Masimo is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Masimo	$2.09B	3.80	-$304.90M	-$8.52	-17.20
Omnicell	$1.11B	1.37	$12.53M	$0.50	66.32

Do insiders and institutionals have more ownership in MASI or OMCL?

86.0% of Masimo shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 16.9% of Masimo shares are owned by company insiders. Comparatively, 2.5% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Summary

Masimo beats Omnicell on 9 of the 16 factors compared between the two stocks.